Biotech Values

[apljack]

NXTM: NxStage Reports Record Second Quarter 2014 Financial Results And Increases Full-Year Revenue Guidance

--Revenue Increases to $74.1 million, up 13% from Q2'13
--Home Revenue Increases to $38.5 million, up 18% from Q2'13
--Company Expects to Top 15% Annual Growth Target for Home in 2014
--Company Increases Full-Year 2014 Revenue Guidance to be between $290 and $293 million.

https://finance.yahoo.com/news/nxstage-reports-record-second-quarter-113800227.html

(This microcap renal dialysis equipment and services co. has now outperformed expectations for the third quarter in a row. It appears that their flagship product NxStage System One, a home hemodialysis system, continues to gain a foothold, with a healthy growth rate of adoption. The co. also runs several dialysis units, sells their NxStage systems to hospitals as their units are small and convenient to use. They need to show they can be profitable, but they are starting to become big enough to start showing up on radar screens as far as a buyout is concerned. Any co. with revenues closing in on $300 million with a market cap of under $1 billion and a relatively sound balance sheet is a target, IMO.)